A Closer Look at Global Health Research and Development

By Staff Writer

December 29, 2023

Advancing Health Research on a Global Scale

Global Observatory on Health Research and Development (R&D) of the World Health Organisation (WHO) has just debuted its most current results. The report’s depiction of severe inequalities in the allocation of resources, money, and capacity for global health research was not unexpected. There is obviously a divide between nations with high incomes and those with low or medium incomes. The publication of this finding in the journal Health Research Policy and Systems highlights the importance of thoroughly reevaluating strategies and financial decisions for health research and development.

The Critical Need to Resolve Past Inequities

The recent COVID-19 pandemic and other outbreaks such as mpox underscore the urgent need for a fairer allocation of health research funds. Despite numerous discussions and proposals, the disparity in resource distribution between wealthy and poor nations remains largely unaddressed. This issue is critical not only for disaster preparedness but also for the global goal of improving population health equitably.

Important Results from the Worldwide Health Research and Development Project

The report highlighted four major issues. In 2020, low-income nations received just 0.2% of all grant funding, highlighting the huge disparity in this area. As a second point, the disparity in research capacity is exacerbated by the fact that high-income nations have around 56 times more health researchers per million resident than low-income countries. Third, there is a dearth of research training possibilities in low-income nations due to the low density of higher education institutions relative to the population. Finally, the suggested goals for health R&D spending as a proportion of GDP were unmet by a number of nations.

The Need to Take Action

Consistent gaps in health research capacity and financing are highlighted by the results. There has been no improvement in decades of acknowledgment. The paper recommends a systematic approach to data collection and prioritises research. It promotes frequent data exchange and advocates for global collaboration in solving these problems.

The Global Observatory on Health Research and Development remains a vital tool today. It monitors and analyses data on health research and development. It highlights both the opportunities and challenges in this crucial sector. If the international community collaborates to bridge the knowledge gap, we can improve health outcomes for all. 

Reference url

Recent Posts

Zimislecel type 1 diabetes
   

Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential

🚀 What if we could revolutionize Type 1 diabetes treatment?

Vertex Pharmaceuticals has made significant strides with its promising phase 1/2 trial results for **zimislecel**, a stem cell-derived therapy that not only restores insulin production but also drastically reduces severe hypoglycemic events. As phase 3 trials commence, this breakthrough could reshape care for T1D patients and potentially reduce long-term healthcare costs.

Curious to learn how zimislecel and other potential cell therapies may redefine diabetes management? Click to read more!

#SyenzaNews #biotechnology #HealthEconomics

biosimilar clinical approach
    

Biosimilar Clinical Approach

🚀 How is the EMA’s new biosimilar clinical approach changing the landscape of drug approvals in Europe?

With a focus on tailored clinical assessments, the EMA is streamlining the pathway for biosimilars by allowing analytical data to take precedence over large-scale comparative efficacy studies. This shift promises to enhance patient access to life-saving therapies while maintaining rigorous safety standards.

Dive deeper into the implications of this innovative regulatory approach and find out how it can impact health economics and market access.

👉 Read more in the full article!
#SyenzaNews #regulatoryaffairs #MarketAccess

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.